ArticleMaedica2026
Orthoptek Magnocellular Stimulation for Amblyopia Across Age Groups: Visual Recovery Beyond Childhood.
Article in Maedica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess the outcome of Orthoptek Magnocellular Stimulator (OMS) therapy on visual acuity, binocular vision and stereopsis in patients with amblyopia across various age groups and to evaluate treatment efficacy. Methods: This prospective observational study included 106 patients with amblyopia who received OMS therapy. A 20-session course (30 minutes per session) was prescribed; actual treatment exposure varied and averaged 5.17 sessions. We assessed outcomes at the last available post-treatment visit (mean follow-up, 36.79 days; median, one day). We compared pre- and post-treatment visual acuity, stereopsis, central macular thickness (CMT) and retinal nerve fibre layer (RNFL) thickness. We performed regression analyses to identify factors associated with the final visual outcome. Results: Study participants' mean age was 17.55 ± 13.91 years. Refractive amblyopia was the most common subtype (67.9%), followed by strabismic amblyopia (30.2%). Mean amblyopic-eye visual acuity improved from 0.97 ± 0.53 to 0.75 ± 0.52 logarithm of the minimum angle of resolution (logMAR) (p < 0.001). Distance stereopsis improved significantly from 349.24 ± 281.62 to 291.05 ± 271.96 arc seconds (p < 0.001), while near stereopsis remained unchanged (p = 0.261). Optical coherence tomography (OCT) showed no clinically meaningful change in RNFL thickness. A small increase in amblyopic-eye CMT was statistically significant (mean change, 6.87 µm; p = 0.013) but was not associated with visual improvement and was considered of uncertain clinical relevance. Baseline visual acuity was the strongest predictor of outcome (β = 0.82, p < 0.001). Greater treatment exposure was independently associated with better visual recovery (β = -0.021, p = 0.014), whereas age, follow-up duration and amblyopia subtype were not significant predictors. Conclusion: Orthoptek Magnocellular Stimulator therapy was associated with improved visual acuity and distance stereopsis. Retinal nerve fibre layer thickness remained stable, while the small statistically significant increase in amblyopic-eye CMT was not associated with visual improvement and had uncertain clinical significance. The absence of an age-related association suggests that visual improvement may be achievable beyond the traditional critical period. These preliminary findings support further controlled evaluation of OMS as a potential adjunct to amblyopia rehabilitation in younger and older patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.